Clinical trials: aldesleukin
Leukemia
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Giving combination chemotherapy before a peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00004128
- Testing
- aldesleukin, filgrastim, busulfan
- Volunteers
- 2,000 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Alzheimer Dementia (AD)
Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.
- Trial name
- NCT07651319
- Testing
- IL-2 (Aldesleukin), Semaglutide Plus IL-2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Methodist Hospital Research Institute
Stage IV Skin Melanoma
Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy
This pilot clinical trial studies aldesleukin imaging in viewing tumor growth in patients with stage IV melanoma receiving ipilimumab or pembrolizumab therapy.
- Trial name
- NCT01789827
- Testing
- Laboratory Biomarker Analysis, Radionuclide Imaging, Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab.
- Conditions
- Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC
- Trial name
- NCT03215810
- Testing
- Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neuroblastoma
Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in childhood, with nearly 50% of patients presenting with widespread metastatic disease.
- Trial name
- NCT01857934
- Testing
- cyclophosphamide, topotecan, hu14.18K322A
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- St. Jude Children's Research Hospital
Recurrent, Platinum-resistant
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating…
- Conditions
- Recurrent, Platinum-resistant, High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT01883297
- Testing
- Re-stimulated tumor-infiltrating lymphocytes (TILs), Interleukin-2, Cyclophosphamide
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University Health Network, Toronto
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.
- Trial name
- NCT03778619
- Testing
- Rituximab, Fludarabine, Cyclophosphamide
- Where
- 3 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- GC Cell Corporation
Renal Carcinoma, Renal Cell Carcinoma
Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma
The goal of this research study is to establish the safety and then to explore the effectiveness of infusing the combination of cytokine-induced memory-like (CIML) natural killer (NK) cells, a type of immune cell in the blood…
- Conditions
- Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma
- Trial name
- NCT06318871
- Testing
- Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, Interleukin-2 (IL-2)
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
MDR TB
Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a challenge worldwide. Few studies have prospectively reported outcomes in patients with pulmonary MDR-TB treated with adjunctive immunotherapy combined to standard…
- Trial name
- rhIL-2 (NCT03069534)
- Testing
- RhIL-2
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Skin Cancer, Melanoma
Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...
Background: Adoptive cell therapy involves taking white blood cells called lymphocytes from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient to allow the cells to…
- Conditions
- Skin Cancer, Melanoma, Metastatic Melanoma
- Trial name
- NCT01118091
- Testing
- Aldesleukin, CD8 enriched Young TIL
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx
This study will examine whether interleukin-2 (IL-2) given before the interruption of antiretroviral (ARV) treatment could significantly extend the period of time that a patient is temporarily not taking ARV treatment and also…
- Trial name
- ILIADE (NCT00071890)
- Testing
- Interleukin 2, HAART, Treatment interruption
- Where
- 2 sites in United States, France
- Volunteers
- 148 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Melanoma (Skin Cancer), Melanoma Metastatic
A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma
The goal of this study is to determine the activity of Perkileucel, a tumour infiltrating lymphocyte (TIL) adoptive cell transfer therapy (ACT), in patients with unresectable stage III or metastatic melanoma who have progressed…
- Trial name
- PERTIL-01 (NCT07651618)
- Testing
- Tumour Infiltrating Lymphocytes Adoptive Cell Therapy, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Aldesleukin
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- East Metropolitan Health Service, Australia
Cervical Cancer, Throat Cancer
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers.
- Conditions
- Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer
- Trial name
- NCT05686226
- Testing
- E7 TCR-T cells, Aldesleukin
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Christian Hinrichs
Metastatic Melanoma, Metastatic Renal Cancer
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Background: Aldesleukin (IL-2) is a drug that can help to shrink tumors in some patients with metastatic renal cancer and metastatic melanoma.
- Trial name
- NCT01160445
- Testing
- Zanolimumab, Aldesleukin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Refractory Cancer
TCR-engineered T Cells in Solid Tumors: IMA202-101
The study purpose is to establish the safety and tolerability of IMA202 product in patients with solid tumors that express melanoma-associated antigen 1 (MAGEA1).
- Conditions
- Solid Tumor, Adult, Refractory Cancer, Recurrent Cancer, Cancer
- Trial name
- ACTengine (NCT03441100)
- Testing
- IMA202 Product, IMADetect®
- Where
- 6 sites in United States, Germany
- Volunteers
- 16 people
- Sponsor
- Immatics US, Inc.
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Single Patient Expanded Access
- Trial name
- NCT04135092
- Testing
- Individual Patient TCR Transduced PBL, Cyclophosphamide, Fludarabine
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Cancer, Melanoma
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
Background: One possible treatment for advanced melanoma involves collecting white blood cells from the person with cancer and growing them in a laboratory. The cells can then be given back to the donor.
- Trial name
- NCT01585415
- Testing
- Vemurafenib, Young TIL, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Chronic Myeloproliferative Disorders
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and peripheral stem cell transplantation with biological therapy may kill more cancer…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer
- Trial name
- NCT00003408
- Testing
- aldesleukin, recombinant interferon alfa, sargramostim
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cancer Treatment Centers of America
Metastatic Melanoma
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Background: In a study in humans with melanoma, patients given total body irradiation to suppress the immune system in conjunction with chemotherapy showed a significant clinical response.
- Trial name
- NCT00314106
- Testing
- Melanoma Reactive TIL, Cyclophosphamide, IL-2
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
The purpose of this study is to evaluate the safety and tolerability of giving IL-2 plus anti-HIV (antiretroviral) therapy to HIV-positive patients with CD4 cell counts (cells of the immune system that fight infection) of at…
- Trial name
- NCT00000948
- Testing
- Aldesleukin, ART
- Where
- 2 sites in Thailand
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)